Our technology at a glance

Our story

Ellele Health was founded in 2024 to advance the next generation of diagnostics across gynaecological conditions through better sampling methods. The company builds on the foundation of its parent company, TOGL, whose proprietary mucosal sampling technology and hologenomic pipeline were used to develop a superior diagnostic for colorectal cancer [1].

Recognising limited innovation in vaginal sampling methods, Ellele Health extends this validated approach to address significant unmet need in gynaecological care. We created the proprietary Ellele Sampling Device to address analytical requirements of the next-generation multiomics-based diagnostics while keeping patients’ comfort and dignity at the centre of the design. We have since used the Ellele Sampling Device to support the discovery of novel biomarkers across gynaecological conditions, starting with ovarian and endometrial cancers.

womb, tube, egg, cell, uterus, tubes

Our mission

We envision a world where every woman has access to early and accurate diagnosis for all gynaecological conditions, across life stages and without discomfort or shame.

Our mission is to use the Ellele Sampling Device to:

  • Maximise the value of a single sample by supporting multiple analytical modalities from one high-quality and high-quantity sample
  • Advance novel biomarker discovery by enabling collection of information-rich samples in indications where tests are currently limited or unavailable
  • Transform diagnostic pathways by replacing highly invasive procedures and offering a more accessible tool suitable for use by any trained healthcare professional

The name Ellele unites allele – the fundamental unit of genetic variation – with elle, the French word for “her”.

It reflects our belief that Women’s Health warrants the same depth of scientific research and innovation that has driven advances across other fields - with empathy and respect.

References

  1. Tock, A. J., et al. (2025) Hologenomic analysis of rectal mucus sampling for detection of adenomatous polyps and colorectal cancer. Nature Communications. 16(1):10876.